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Abstract
BACKGROUND: Molecular predictors for the effective-
ness of adjuvant chemotherapy in colorectal cancer
are of considerable clinical interest. To this aim, we
analyzed the serine threonine receptor–associated
protein (STRAP ), an inhibitor of TGF-b signaling, with
regard to prognosis and prediction of adjuvant 5-FU
chemotherapy benefit. METHODS: The gene copy sta-
tus of STRAP was determined using quantitative real-
time polymerase chain reaction in 166 colorectal tumor
biopsies, which had been collected from a randomized
multicenter trial of 5-fluorouracil (5-FU)/mitomycin C
(MMC) adjuvant chemotherapy of the Swiss Group for
Clinical Cancer Research (SAKK). RESULTS: Amplifica-
tion of STRAP was found in 22.8% of the tumors. When
left without adjuvant chemotherapy, patients bearing
tumors with a STRAP amplification had a significantly
better prognosis (hazard ratio for death: 0.26; P = .004).
Interestingly, these patients, when receiving adjuvant
treatment, had a worse survival (hazard ratio for death:
3.48; P = .019) than without chemotherapy, whereas
patients carrying tumors with diploidy or deletion of
STRAP benefited from the treatment (hazard ratio for
death: 0.44; P = .052). This suggests the amplification
of STRAP as a strong predictor of an unfavorable
effect of 5-FU–based adjuvant chemotherapy. CON-
CLUSION: If confirmed, the STRAP gene copy status
might provide a parameter to decide about the use of
5-FU–based adjuvant chemotherapy.
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Introduction
The benefit of adjuvant chemotherapy in colorectal cancer
has been assessed in large phase III trials for which patients
had been selected with regard to tumor stage as the stron-
gest indicator of prognosis. In stage III carcinoma of the
colon, adjuvant chemotherapywith 5-fluorouracil (5-FU) and
leucovorin has become a standard treatment because a
significant increase of time to relapse and a 10% to 12%
absolute improvement in overall survival (OS) have been
shown.Thebenefit of adjuvant chemotherapy in stage II patients
who have a better prognosis is less clear and remains contro-
versial [1]. However, even in patients with stage III disease,
approximately 40% can be cured by surgery alone, and around
50% will die within 5 years despite adjuvant treatment. There-
fore, molecular markers predicting the benefit of adjuvant che-
motherapy in an individual patient are urgently needed.
Generally, predictive markers are molecules involved in the
metabolism of cytotoxic agents or in signaling pathways lead-
ing to cell proliferation, growth control, and apoptosis. As
potential targets of 5-FU–containing regimens, thymidilate
synthase (TS), dihydropyrimidine dehydrogenase (DPD), and
thymidilate phosphorylase (TP), as well as p53, BCL-2 (B-cell
CLL/lymphoma 2), and microsatellite instability (MSI) have
been analyzed [2]. High expression levels of TS [3], DPD [4],
and TP [5] mRNA were associated with resistance to 5-FU
treatment in some—but not all—studies and, similarly, the role
of p53 as a predictive marker in the clinical situation is still
unclear [6]. High expression of BCL-2, an inhibitor of apoptosis,
correlates with improved survival, and early reports suggested
that BCL-2 expression is a predictive marker for a 5-FU
response [7]. However, confirmatory studies are needed before
BCL-2 expression can be used to guide decisions on adjuvant
chemotherapy of colorectal cancer. Finally, MSI, a marker of
functional deficiency of mismatch repair genes, has been
associated with an increased likelihood of 5-FU benefit in one
report [8], whereas others [9] did not confirm this finding. In
summary, none of the potential predictive molecular markers is
sufficiently evaluated to be used in the decision for or against
adjuvant chemotherapy of colorectal cancer.
Sporadic colorectal cancer develops as a result of an ac-
cumulation of genetic alterations [10], including the inactivation
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of the adenomatous polyposis coli (APC)/b-catenin pathway,
mutation of the k-RAS gene, deletion of chromosome 17p
(the genetic locus of the p53 gene), and loss of chromosome
18q harboring deleted in colorectal cancer (DCC) and the
TGF-b signal– transducing molecules SMAD2 [mothers
against decapentaplegic (MAD), Drosophila, homolog 2],
SMAD4, and SMAD7 [11]. The importance of the TGF-b
pathway in colorectal tumorigenesis is underlined by the
finding of inactivating mutations of the TGF-b receptor II,
SMAD2, SMAD4, and TGF-b itself [12–14]. It therefore has
been speculated that most colorectal cancers carry an
alteration in at least one component of the TGF-b signaling
pathway [15].
The serine threonine receptor – associated protein
(STRAP) is a TGF-b pathway inhibitor interacting at the
receptor level. It associates with the TGF-b I and II receptors
[16], and overexpression has been shown to inhibit TGF-b–
mediated activation of transcription. Specifically, STRAP
synergizes with SMAD7, an antagonistic SMAD, in the
inhibition of TGF-b signaling by preventing the access of
SMAD2 and SMAD3 to the receptor [17].
To test whether STRAP is of prognostic value or predic-
tive for chemotherapy benefit, we analyzed a collection of
tumor specimens from a randomized trial of the Swiss Group
for Clinical Cancer Research (SAKK 40/81) evaluating the
effect of 5-FU–based adjuvant chemotherapy in stage II and
stage III colorectal cancer [18]. The gene dosage of STRAP
in the tumors was determined by quantitative real-time
polymerase chain reaction (PCR) and the gene copy status
was correlated with survival data.
Patients and Methods
Patients
Paired primary tumor and normal tissue biopsies were
obtained from patients involved in a randomized trial on the
benefit of 5-FU/MMC adjuvant chemotherapy versus surgery
alone (SAKK study 40/81) [18]. The adjuvant treatment
consisted of an immediate postoperative infusion with 5-FU
(500 mg/m2 per day) for 7 days and one single dose of
mitomycin C (MMC; 10 mg/m2) on day 1. The SAKK 40/81
trial population comprised 533 patients younger than 75
years with a median of 62 years. About 63.4% of the patients
had colonic carcinomas and 36.6% had rectal carcinomas.
A total of 62.4% were node-negative (stage II) and 31.1%
were node-positive (stage III); in 6.5%, the nodal status was
not assessed. Details of the trial have been described
previously [18]. The subpopulation of which tumor speci-
mens were successfully analysed for STRAP gene copy
status (Table 1, first column) was very similar to the whole
SAKK 40/81 trial population with respect to age, stage, and
tumor location. The study was approved by the local ethics
committees of the participating institutions.
Methods
Genomic DNA was extracted from formalin-fixed and
paraffin-embedded tumor and normal tissue biopsies derived
from the same patients using the Nucleospin C+T kit
(Macherey-Nagel, Du¨rren, Germany), according to the man-
ufacturer’s instructions.
The gene copy status of STRAP was established by gene
dosage with real-time quantitative PCR using the TaqMan
system on an ABI Prism 7700 sequence detector (PE
Applied Biosystems, Foster City, USA), as described previ-
ously [19]. The protocol for gene dosage is given in Boulay
et al. [19]. To identify the human STRAP gene (AB 024327:
MAWD, Homo sapiens pt-wd mRNA for WD-40 repeat
protein), the following primers were selected: STRAP f,
cgcgacccgtggttga; STRAPr, aagcgctgattaagaaatacccata;
probe: STRAP, ttggccttcagtggcatcacgc.
For each individual, the Ct value obtained for the autoso-
mal reference gene 36B4 (calculated by the built-in software)
on normal tissue was subtracted from that of the tumor
tissue, thus defining DCt 36B4. An analogous calculation
was made for STRAP. The gene copy status is indicated by
Table 1. Clinical Characteristics of Colorectal Cancer Patients from the SAKK 40/81 Trial Whose Tumors Were Evaluated for the STRAP Gene Copy Status.
All patients (n = 166) Amplification (n = 38) Deletion (n = 75) Normal Diploidy (n = 53) P (Fisher’s Exact Test)
Median age (years) 63 61 63 63
Sex [n, (%)]
Male 79 (48) 20 (53) 37 (49) 22 (42) .56
Female 87 (52) 18 (47) 38 (51) 31 (58)
Lymph node status [n, (%)]
Positive 57 (34) 14 (37) 22 (29) 21 (40) .69
Negative 102 (62) 23 (61) 50 (67) 29 (55)
Missing information 7 (4) 1 (3) 3 (4) 3 (6)
Tumor size [n, (%)]
Locally advanced (T stage z 3) 125 (75) 31 (82) 55 (73) 39 (74) .60
Locally not advanced (T stage < 3) 41 (25) 7 (18) 20 (27) 14 (26)
Tumor location [n, (%)]
Rectum 45 (27) 13 (34) 16 (21) 16 (30) .29
Colon 121 (73) 25 (66) 59 (79) 37 (70)
Adjuvant chemotherapy [n, (%)]
Yes 65 (39) 17 (45) 24 (32) 24 (45) .23
No 101 (61) 21 (55) 51 (68) 29 (55)
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the DCt value (DCt 36B4  DCt STRAP) as follows: 0.45 <
DCt < 0.45: normal diploidy; DCt < 0.55: deletion; DCt >
0.55: amplification. Molecular analysis was performed
blinded to the clinical data.
Statistical Analysis
Two multiple Cox regression models were performed to
test the prognostic and predictive values of STRAP status
separately on disease-free survival (DFS) and OS. Main
effects of STRAP status were represented by two covariates:
amplification and deletion, with no change at the reference
level. Interaction effects between STRAP status and treat-
ment were represented by two interaction terms: treatment
amplification and treatment  deletion. In addition to cova-
riates of STRAP and treatment indicator, five known prog-
nostic factors (i.e., patients’ age at trial entry, sex, lymph
node status, tumor size, and tumor location) were also
included in the regression analysis as confounding variables
to control for their influence. The Cox regressions were
performed on 159 of 166 STRAP-informative patients be-
cause the clinical data were incomplete for seven of them
(Table 1).
The test for prognostic effects was based on the statistical
significance of the coefficients for the terms gene amplifica-
tion and gene deletion, and the test of predictive effects on
the treatment  amplification or treatment  deletion inter-
action terms. A significant treatment  amplification interac-
tion would mean that the risk for patients with amplification
relative to patients without change at the STRAP locus
differs between untreated and treated patients. Analogously,
it also would mean that the relative risk of treated versus
untreated patients differs between patients with STRAP
amplification and those with no change. The same logic
applies for the treatment  deletion interaction. Survival
curves were constructed with the Kaplan-Meier method.
Following regression, diagnostics was employed to check
the quality of our Cox models [20]. For each covariate, we
graphically checked the scaled Schoenfeld residuals and ran
a test to check proportional hazard assumption that underlies
the use of Cox regressions; deviance residuals were plotted
to discover patients who are poorly predicted by our statis-
tical models; score residuals were plotted to discover indi-
vidual patients who have a large influence on the models.
Results
To determine the prevalence of STRAP amplifications and
STRAP deletions in early colorectal cancer, we analyzed 182
paired tumor and non-neoplastic DNA specimens collected
from patients of the SAKK 40/81 trial. Of the 182 specimens,
166 (91%) were informative for the STRAP gene copy status.
Complete or partial allelic loss of STRAP was found in 75
(45.2%), normal diploidy in 53 (32%), and gene amplification
in 38 (22.8%) tumors, respectively. We did not find any
statistically significant association between STRAP gene
copy status (amplification, deletion, and normal diploidy) and
either gender, tumor size, lymph node status, tumor location,
or received treatment (Table 1). These clinical characteristics
were similar for all three subgroups. A summary table with
these clinical characteristics of individual patients further
illustrates the absence of an association of STRAP amplifi-
cation with any specific combination of them (Table 2).
In patients who did not receive adjuvant treatment (control
arm of the SAKK 40/81 trial), the STRAP gene copy status
was prognostic for DFS and OS. Compared to patients with
normal diploidy at the STRAP locus, amplification of STRAP
significantly reduced the relative risk of recurrence (P = .005)
and the relative risk of death (P = .004) (Table 3). Patients
with STRAP amplification in their tumors showed a much
better DFS and OS than patients harboring tumors with
normal diploidy of STRAP (Figure 1A). Contrary to STRAP
amplification, STRAP deletion did not have any statistically
significant association with either DFS or OS (Table 3).
Because there was no significant association of STRAP
deletion and survival, we pooled patients bearing tumors
with normal diploidy or deletion of STRAP (‘‘no amplifica-
tion’’) and compared them to patients with tumors harboring
a STRAP amplification. This analysis, including all patients
who did not receive adjuvant chemotherapy, allows testing
whether STRAP amplification separates a specific prognos-
tic subgroup from the rest of the patients. In fact, a significant
prognostic effect of STRAP amplification was confirmed with
respect to DFS (P = .011) and OS (P = .020) (Table 3 and
Figure 1B). Because our multivariable Cox regressions
contain sex, tumor size, lymph node stage, and tumor
location as covariates, the hazard ratio for STRAP amplifi-
cation is adjusted for these variables (i.e., the results for
STRAP amplification are independent of any effects of sex,
size, lymph node stage, and tumor location). These findings
suggest a role of STRAP amplification as an independent
favorable prognostic marker in early colorectal cancer.
Among patients who received adjuvant 5-FU/MMC che-
motherapy, we also found a significant association of the
STRAP gene copy status with prognosis. But surprisingly,
chemotherapy-treated patients bearing tumors with STRAP
amplification had a significantly shorter DFS [HR for relapse
2.61 (1.05–6.48), P = .039] and a trend toward worse OS
[HR for death 2.05 (0.79–5.37), P = .140] than patients
bearing tumors with normal diploidy at the STRAP locus.
Thus, the effect of the STRAP gene copy status differed
between the treatment groups.
Because the patients from whom tumor specimens were
collected were randomized to receive perioperative adjuvant
5-FU/MMC chemotherapy or no adjuvant treatment [18], we
were able to test whether the gene copy status of STRAP
was correlated with the treatment effect. With regard to DFS,
the significant interaction of STRAP amplification and treat-
ment (treatment amplification interaction term: hazard ratio
for relapse = 9.58; P = .001) (Table 4) showed that the
STRAP status can predict the effect of treatment. Specifi-
cally, among patients with tumors having normal diploidy of
STRAP, those receiving adjuvant treatment had a relative
risk of relapse of .42 (P = .041) compared with those without
adjuvant therapy (i.e., they derive a significant benefit
from the treatment) (Table 5). On the other hand, among
patients bearing tumors with an amplification of STRAP,
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those receiving adjuvant treatment had a 4.07 times higher
relative risk of relapse (P = .006) than those without adjuvant
therapy (Table 5). These results are illustrated by Figure 2, A
and B, which shows a better DFS for treated patients in the
group with normal diploidy of STRAP, but a worse DFS for
treated patients in the group with STRAP amplification.
Similarly, there was a significant interaction between treat-
ment and STRAP amplification with regard to OS (P = .003).
Treatment with 5-FU/MMC reduced the relative risk of death
to .44 (P = .052) in patients bearing tumors with normal
diploidy of STRAP, whereas it increased the relative risk of
death 3.48-fold (P = .019) in patients carrying a tumor with
STRAP amplification.
Contrary to STRAP treatment  amplification interaction,
STRAP treatment  deletion interaction did not show a
statistically significant association with either DFS or OS
(DFS: treatment  deletion: HR = 0.38, P = .190; OS:
treatment  deletion: HR = 0.28, P = .140). This allows us
to compare patients with tumors harboring a STRAP ampli-
fication to pooled patients with normal diploidy or deletion of
STRAP (‘‘no amplification’’). The results of this analysis were
highly significant (P < .001), confirming the strong predictive
relevance of STRAP amplification (Table 4). The survival
curves of all patients without amplification of STRAP (‘‘no
amplification’’ group) illustrate the high benefit they derive
from 5-FU/MMC adjuvant therapy (Figure 2C) similar to the
patients with tumors containing a normal diploidy of STRAP
(Figure 2A).
The analysis of Schoenfeld residuals did not show any
evidence of departure from the proportional hazards as-
sumption. Deviance residuals did not identify any patients
Table 2. Clinical Characteristics of Individual Patients with STRAP Amplification of Their Tumors.
Patient ID Number Age (years) Sex Lymph Node Status Tumor Size Tumor Location
8 66 Female Positive Locally advanced Colon
9 71 Female Positive Locally advanced Colon
17 54 Male Positive Locally advanced Colon
34 46 Female Negative Locally advanced Colon
36 65 Male Negative Locally advanced Colon
43 55 Male Negative Locally advanced Colon
54 57 Male Negative Locally advanced Colon
83 49 Female Positive Locally advanced Colon
150 60 Male Negative Locally advanced Colon
164 70 Male Negative Locally advanced Colon
271 72 Male Negative Locally advanced Colon
290 73 Male Negative Locally not advanced Colon
357 60 Female Negative Locally advanced Colon
359 64 Male Negative Locally advanced Colon
365 60 Female Negative Locally advanced Colon
372 64 Female Negative Locally advanced Colon
379 44 Female Negative Locally not advanced Colon
383 39 Female Negative Locally advanced Colon
384 62 Male Positive Locally advanced Colon
393 59 Female Negative Locally advanced Colon
418 66 Female Negative Locally advanced Rectum
443 54 Male Negative Locally advanced Rectum
452 50 Male Positive Locally not advanced Rectum
453 74 Male Positive Locally advanced Rectum
455 59 Male NA Locally not advanced Rectum
456 48 Female Negative Locally not advanced Rectum
478 59 Female Positive Locally advanced Rectum
482 59 Male Positive Locally not advanced Rectum
488 71 Female Negative Locally advanced Rectum
529 74 Male Negative Locally advanced Colon
550 68 Female Negative Locally advanced Rectum
560 66 Female Positive Locally advanced Colon
564 62 Female Positive Locally advanced Colon
567 44 Male Negative Locally advanced Colon
573 70 Male Positive Locally not advanced Colon
636 63 Female Positive Locally advanced Rectum
652 60 Male Negative Locally advanced Rectum
655 65 Male Positive Locally advanced Rectum
NA = not assessed.
Table 3. Prognostic Relevance of STRAP Gene Copy Status in Patients
Without Adjuvant Chemotherapy.
Markers Relative Risk
of Recurrence
(95% CI)
P Relative Risk
of Death
(95% CI)
P
Amplification (n = 20)
versus normal
diploidy (n = 27)
0.27 (0.11–0.68) .005 0.26 (0.10–0.70) .004
Deletion (n = 48) versus
normal diploidy (n = 27)
0.71 (0.35–1.36) .280 0.60 (0.25 –1.05) .130
Amplification (n = 20)
versus no amplification
(n = 75)
0.34 (0.15–0.79) .011 0.37 (0.16–0.85) .020
The relative risk has been calculated using a multivariate Cox proportional
hazard model. The relative risk of patients with normal diploidy of STRAP is 1.
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who were poorly predicted by our models. No single obser-
vations showed a large influence on the multivariate models.
Because all our multivariable Cox regressions contain gen-
der, age at study entry, site, and stage of disease as
covariates, the hazard ratios for treatment, amplification,
and their interaction are adjusted for these confounding
parameters. Thus, our findings strongly support a role of
STRAP amplification as an independent negative predictive
marker for 5-FU–based chemotherapy benefit in early colo-
rectal cancer patients.
Figure 1. Prognostic effect of STRAP amplification on DFS and OS in the untreated patient group. (A) Kaplan-Meier curves for DFS and OS of patients without
adjuvant chemotherapy who are harboring tumors with STRAP amplification versus tumors with normal diploidy of STRAP. In the absence of adjuvant
chemotherapy, the patients with tumors displaying STRAP amplification had a significantly longer DFS and higher OS [relative risk of recurrence: 0.27 (95%
confidence interval: 0.11–0.68, P = .005) and relative risk of death: 0.26 (95% confidence interval: 0.10–0.70, P = .004)]. (B) Kaplan-Meier curves for DFS and
OS of all patients without adjuvant chemotherapy. Patients harboring tumors with STRAP amplification versus pooled patients with tumors containing diploidy or
deletion of STRAP (‘‘no amplification’’).
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Discussion
Adjuvant chemotherapy of colorectal cancer is impaired by
at least two major obstacles: the lack of efficacy of current
standard treatments, and our inability to predict which
patients will derive benefit from this frequently toxic interven-
tion. Response rates to modern chemotherapy regimens in
advanced disease, containing eloxatin and/or CPT-11
[21,22], have given rise to the hope that improved survival
might be achievable in patients with early colorectal cancer,
but results of phase III trials comparing these regimens to
standard 5-FU–based adjuvant treatments are pending.
We have determined the prevalence of STRAP deletions
and amplifications in a large number (n = 166) of patients
with colorectal cancer. Amplification of STRAP in 22% of the
tumors is in line with the published amplification frequency
of chromosome 12p12, where STRAP is located, which has
been found in 9 of 30 primary colon carcinomas using
comparative genomic hybridization [23]. Interestingly, chro-
mosome 12p12 has also been described to be amplified in
pancreatic, gastric, oral squamous cell, and testicular germ
cell cancers, suggesting a broader role for this molecular
alteration in tumorigenesis [24]. In addition to amplification,
we have also observed the frequent deletion of the STRAP
locus, again in line with findings in several other tumor
entities, such as ovarian cancer, childhood acute lymphatic
leukemia, and prostate carcinoma [25].
Patients in the control arm of the 40/81 study who did not
receive adjuvant therapy allowed us to determine the true
survival advantage of patients whose tumors had a STRAP
amplification. Although amplified in only around 22% of the
tumors, STRAP turned out to be an independent prognostic
marker for better DFS (P = .0098) as well as OS (P = .0054)
(Table 3). It is tempting to speculate that the positive prog-
nosis associated with amplification of STRAP is explained by
the increased formation of the STRAP/SMAD7 complex, one
of the physiological pathways of inhibition of TGF-b signaling,
and thus tumor cell proliferation. In a recent study, amplifi-
cation of STRAP was uniformly associated with overexpres-
sion of its protein product in the cytoplasm of 21 of 46 breast
cancer tissue specimens compared with matched normal
breast tissues [26]. Assuming that in colorectal cancer
STRAP amplification also leads to protein overexpression,
it is conceivable that the TGF-b pathway is inhibited more
efficiently by STRAP in tumors carrying an amplification of
this gene. Because in late tumor stages TGF-b signaling has
been shown to enhance tumor progression [27], amplifica-
tion of a TGF-b pathway inhibitor should be protective and
lead to a more favorable prognosis. Results of preliminary
in vitro experiments in our laboratory showing an inhibition
of proliferation of tumor cell lines when STRAP is overex-
pressed (data not shown) are well in line with this hypothesis.
Our data are also in accordance with the observation of
Markowitz et al. [12], who found a better prognosis of
hereditary nonpolyposis colon cancer patients carrying inac-
tivating mutations of the TGF-b II receptor.
By far, the most interesting finding of our study is the
deleterious effect of adjuvant chemotherapy on patients with
a STRAP-amplified carcinoma. These patients had a nearly
three-fold better chance to be alive and free of disease if left
untreated compared to the same molecularly defined group
of patients after treatment with adjuvant chemotherapy
(Tables 4 and 5, Figure 2). Obviously, this leaves patients
without STRAP amplification with a correspondingly higher
benefit of adjuvant treatment compared with an unselected
group of patients with colorectal cancer.
Our data on STRAP amplification as a predictive factor for
chemotherapy benefit might help to better select patients for
future adjuvant chemotherapies in colorectal cancer. How-
ever, this analysis of a molecular marker for chemotherapy
benefit is limited by the inherent problem of many similar
analyses i.e., that a treatment regimen for which mature
clinical follow-up data are available has frequently been
replaced by a more modern standard when the molecular
analyses are performed. A further limitation of our study
relates to the fact that we cannot formally separate the
Table 4. Predictive Value of STRAP Amplification.
STRAP Relative Risk
of Recurrence
(95% CI)
P Relative Risk
of Death
(95% CI)
P
STRAP amplification
(n = 37) versus normal
diploidy (n = 50)
9.58 .001 7.95 .003
STRAP amplification
(n = 37) versus no
amplification (n = 122)
12.79 <.001 10.37 <.001
The amplification  treatment interaction in the multivariate proportional
hazard model is highly significant for DFS and OS in comparison to either
patients with diploidy of strap in their tumors, or to pooled patients with tumors
containing diploidy or deletion of strap (no amplification).
Table 5. Influence of STRAP Gene Copy Status on Treatment Effect.
Markers Relative Risk of Recurrence (95% CI) P Relative Risk of Death (95% CI) P
STRAP normal diploidy
Treated (n = 23) versus untreated (n = 27) 0.42 (0.19–0.96) .041 0.44 (0.19–1.01) .052
STRAP amplification
Treated (n = 17) versus untreated (n = 20) 4.07 (1.51–11.00) .006 3.48 (1.23–9.85) .019
STRAP no amplification
Treated (n = 48) versus untreated (n = 80) 0.32 (0.17–0.62) <.001 0.33 (0.17–0.66) .002
The relative risk of patients who did not receive adjuvant chemotherapy is 1.
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potential effects of the two drugs within this regimen. Al-
though the perioperative 5-FU/MMC treatment regimen used
in the SAKK 40/81 trial is not today’s clinical standard, it was
clearly shown to be an effective treatment in this population
[18]. Taking these limitations into consideration, it seems
plausible that the predictive value of STRAP amplification we
have shown for short-term adjuvant 5-FU/MMC might also
be present when the current standard regimen of 6 months of
5-FU/leucovorin or future eloxatin and/or CPT-11–contain-
ing regimens is analyzed. This hypothesis, however, needs
to be tested in independent large, randomized trials.
How can this provocative finding be explained? Because
patients harboring tumors with an amplification of STRAP
have a higher relapse and death rate with than without
adjuvant chemotherapy, 5-FU resistance cannot explain this
finding. It must result from a direct unfavorable effect of 5-FU
on tumor biology in this situation. On a purely descriptive
level, 5-FU seems to abolish the positive prognostic effect of
STRAP amplification because the survival of patients har-
boring tumors with a STRAP amplification after adjuvant
chemotherapy is very similar to the survival of patients with
a normal diploidy of STRAP in their tumors when left without
adjuvant chemotherapy (Figure 2, A and B).
We have reported that deletion of another member of the
TGF-b signaling pathway, SMAD4, was also associated with
reduced benefit of 5-FU/MMC adjuvant chemotherapy in the
same collection of tumor specimens [28]. Because SMAD4
is an agonist and STRAP is an antagonist in the TGF-b
pathway, it is consistent that deletion of the first and ampli-
fication of the latter have the same effect on chemotherapy
efficacy. Certainly, these two studies suggest that the
effect of 5-FU–based chemotherapy might be dependent
on TGF-b signaling. In vitro experiments, which demonstrate
that 5-FU inhibits TGF-b–induced expression of collagen
type I in fibroblasts through JNK/AP-1 activation [29], support
this hypothesis of an interference between 5-FU and TGF-b
signaling. In the context of STRAP amplification 5-FU might
lead to a severe imbalance in the TGF-b signaling pathway,
which provokes an activation of undetectable residual neo-
plastic cells after removal of the primary tumor.
In conclusion, amplification of STRAP defines a subgroup
of colorectal cancer patients with a favorable prognosis, who,
according to current clinical standards, would receive adju-
vant chemotherapy with a deleterious effect. Limiting treat-
ment to those patients who are likely to benefit might spare a
substantial minority of patients the side effects of a useless
or even harmful chemotherapy, and thus decrease the
ineffective use of resources and, perhaps, improve long-
term results. If confirmed, determination of the STRAP gene
copy status might be a helpful parameter in the management
of patients with stage II and stage III colorectal cancer.
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